Results of a 6-Month, Multicenter, Open-Label, Prospective Study Concerning Efficacy and Safety of Mycophenolate Sodium in De Novo Kidney Transplant Recipients

Transplantation Proceedings

Volumn 39, Issue 9, 2007, Pages 2730-2732

  Wyzgal J ^a   Niemczyk, M ^a   Ziolkowski J ^a   Durlik, M ^a   Wiecek, A ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID; STEROID;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LYMPHOCELE; MALE; MULTICENTER STUDY; OPEN STUDY; OSTEOPOROSIS; POLAND; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SURVIVAL; URINARY TRACT INFECTION;

ADULT; CREATININE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; REOPERATION; SAFETY;

EID: 36049011324     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.08.071     Document Type: Article

References (6)

1. Bunnapradist S., Lentine K.L., Burroughs T.E., et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82 (2006) 102
2. Chan L., Mulgaonkar S., Walker R., et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81 (2006) 1290
3. Vogt B., Antoniadis A., Klinger M., et al. Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study. Transplant Proc 38 (2006) 1301
4. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
5. Budde K., Curtis J., Knoll G., et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: resultts of a 1-year study. Am J Transplant 4 (2004) 237
6. Schlavelli R., Gaite L., Agost Carreno C., et al. Use of enteric-coated mycophenolate sodium in de novo renal transplant recipients with high incidence of delayed graft function. Transplant Proc 38 (2006) 905